Antidiabetic GLP-1s only linked to thyroid cancer in rodents, study suggests
This article was originally published in Scrip
Executive Summary
Thyroid cancer risks of anti-diabetic GLP-1 analogues are probably limited to rats and mice, suggests Novo Nordisk-sponsored research published this week in the journal Endocrinology. Investors, who had been expecting the good news, nevertheless breathed a sigh of relief for the emerging injectable drug class, which includes Lilly/Amylin's twice-daily Byetta (exenatide) and Novo Nordisk's once-daily Victoza (liraglutide).